StockData
Annovis Bio, Inc. logo

Annovis Bio, Inc. (ANVS) stock

ANVSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.74−0.01 (-0.91%)

Close on Nov 17, 2026Market cap $31.66MP/E –Yield –

Annovis Bio operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Annovis Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$43.34M. For fiscal 2025 it was -$25.62M. The highest annual figure on record is -$476.54K in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$25.62M–
FY2024Dec 31, 2024-$21.89M–
FY2023Dec 31, 2023-$39.97M–
FY2022Dec 31, 2022-$17.31M–
FY2021Dec 31, 2021-$9.13M–
FY2020Dec 31, 2020-$3.97M–
FY2019Dec 31, 2019-$476.54K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$21.91M–
Q1 FY2026Mar 31, 2026-$9.01M–
Q4 FY2025Dec 31, 2025-$8.93M–
Q3 FY2025Sep 30, 2025-$3.49M–
Q2 FY2025Jun 30, 2025-$5.11M–
Q1 FY2025Mar 31, 2025-$8.10M–
Q4 FY2024Dec 31, 2024-$8.29M–
Q3 FY2024Sep 30, 2024-$3.20M–
Q2 FY2024Jun 30, 2024-$3.38M–
Q1 FY2024Mar 31, 2024-$7.03M–
Q4 FY2023Dec 31, 2023-$9.36M–
Q3 FY2023Sep 30, 2023-$9.37M–
Q2 FY2023Jun 30, 2023-$9.61M–
Q1 FY2023Mar 31, 2023-$11.63M–
Q4 FY2022Dec 31, 2022-$3.61M–
Q3 FY2022Sep 30, 2022-$3.99M–
Q2 FY2022Jun 30, 2022-$6.69M–
Q1 FY2022Mar 31, 2022-$3.02M–
Q4 FY2021Dec 31, 2021-$1.77M–
Q3 FY2021Sep 30, 2021-$1.74M–
Q2 FY2021Jun 30, 2021-$3.14M–
Q1 FY2021Mar 31, 2021-$2.47M–
Q4 FY2020Dec 31, 2020-$765.95K–
Q3 FY2020Sep 30, 2020-$922.66K–
Q2 FY2020Jun 30, 2020-$1.31M–
Q1 FY2020Mar 31, 2020-$970.41K–
Q4 FY2019Dec 31, 2019-$52.53K–
Q3 FY2019Sep 30, 2019-$44.68K–
Q2 FY2019Jun 30, 2019-$150.59K–
Q1 FY2019Mar 31, 2019-$228.74K–

More Annovis Bio figures

See a number that looks wrong?